JB CHEMICALS & PHARMACEUTICALS LTD
EARNINGS PRESENTATION Q4 FY 20
Jyotindra B Mody : Chairman & Managing Director
Shirish B Mody : Whole Time Director - Marketing
Pranabh Mody : WholeTime Director & President
|
JB Chemicals and Pharmaceuticals
(in Rs. Cr.)
|
Mar '20
|
Dec '19
|
Sep '19
|
Jun '19
|
Mar '19
|
YOY
|
QOQ
|
|
Net Sales
|
443.57
|
428.63
|
456.42
|
446.11
|
418.92
|
5.88
|
3.49
|
|
P/L Before Exceptional Items &
Tax
|
77.02
|
88.37
|
101.51
|
91.99
|
68.28
|
12.8
|
-12.84
|
|
Exceptional Items
|
-10
|
--
|
--
|
--
|
--
|
||
|
P B T
|
67.02
|
88.37
|
101.51
|
91.99
|
68.28
|
-1.85
|
-24.16
|
|
Tax
|
16.95
|
21.93
|
7.75
|
29.87
|
21.49
|
-21.13
|
-22.71
|
|
Net Profit
|
50.07
|
66.45
|
93.76
|
62.11
|
46.79
|
7.01
|
-24.65
|
|
Equity
|
15.46
|
16.05
|
16.05
|
16.05
|
16.05
|
-3.68
|
-3.68
|
|
Basic EPS (FV :RS.2)
|
6.3
|
8.26
|
11.67
|
7.73
|
5.68
|
10.92
|
-23.73
|
|
MP
|
701.00
|
Jun 29, 15:14
|
|||||
|
Volume
|
262,964
|
||||||
|
PE
|
27.81746
|
||||||
|
52 Wk L/H
|
321.7
|
743
|
|||||
|
Valuation
|
|||||||
|
Market
Cap (Rs Cr.)
|
|||||||
|
5,427.91
|
|||||||
|
P/E
|
20.2
|
||||||
|
Book
Value (Rs)
|
187.01
|
||||||
|
Dividend
(%)
|
550
|
||||||
|
Industry
P/E
|
31.26
|
||||||
|
EPS
(TTM)
|
34.7
|
||||||
|
Price/Book
|
3.76
|
||||||
|
Dividend
Yield.(%)
|
1.57
|
||||||
|
Face Value (RS)
|
2
|
||||||
· JB
PHARMA’S 4 BRANDS ARE AMONGST TOP 300 IPM BRANDS IN INDIA
· WORLD
CLASS MANUFACTURING FACILITIES WITH APPROVALS LIKE USFDA AND EUGMP
· WELL
DIVERSIFIED ACROSS DIFFERENT EXPORT GEOGRAPHIES
· CONSISTENT
DIVIDEND TRACK RECORD
· STRONG
CASH FLOWS
· DEBT
FREE COMPANY
· STRATEGIC
FOCUS ON CHRONIC SEGMENT
· OVER
2000 DOMESTIC FIELD FORCE
·
Mfg facilities are located in Gujarat and Daman with USFDA approved
tablet plant and API Plants
·
Ranked 34th as per IQVIA & ranked 19th
in Rxns.
·
Domestic Formulations : 42%
·
Branded Generic Esports : 31%
·
CMO 10%
·
US Generics 8%
·
API 4%
·
Contrast Media
3%
·
Others 2%
Q4 FY 20-
OPERATIONAL HIGH LIGHTS
1. DOMESTIC
FORMULATIONS BUSINESS REGISTERED GROWTH OF 24% YOY
2. EXPORT
BUSINESS GOT AFFECTED DUE TO LOCK DOWN DURING MARCH END AND DECLINED BY 6% YOY
3. GROWTH IN ANDA
BUSINESS GOT AFFECTED DUE TO API SUPPLY
ISSUE AT VENDOR LOCATION
4. MARGIN
IMPROVEMENT DUE TO BETTER PRODUCE MIX AND COST OPTIMISATION - HELPED IMPROVE
THE OPERATING PROFIT DURING THE FINANCIAL YEAR
5. COMPANY
OPTED FOR LOWER RATE OF TAX OF 25.17% AS PER SEC. 115BAA
6. MADE
PROVISION OF RS.10 CR FOR COMPENSATION ORDERED BY SC JUDGMENT DT 1-4-2020
7. RECOMMENDED
FINAL DIVIDEND OF Rs.1/SHARE FOR FY 20. HAD DECLARED INTERIM DIVIDEND OF RS.10/SH
IN MAR 2020
8. CONSEQUENT
TO CURRENT PANDEMIC, COMPANY HAS EXPERIENCED SLOW DOWN IN THE SALE OF PRODUCTS IN ACUTE SEGMENT DUE TO CLOSURE
OF CLINICS AND USE OF HOSPITALS LARGELY FOR COVID PATIENTS. THIS COULD ALSO
IMPACT PERFORMANCE OF THE LAUNCH OF NEW PRODUCTS.
9. FY 20
PARTICULARS FY 20 FY 19 YOY
10.
OPERATING REVENUE 1774.7 1643.2 8%
11.
EBITDA 377.5 305.8 4.5%
12.
EBITDA MARGIN 21.27% 18.61% 266BPS
13.
PBT 348.9 287.0 21.6%
14.
PAT 272.4 194.0 40.4%
15.
PAT MARGIN% 15.35% 11.81% 354
BPS
16.
BASIC EPS 34.20% 23.54 45.3%
SHARE
HOLDING PATTERN AS ON 31ST MARCH
PROMOTERS 56%
PUBLIC 23%
MF/INSURANCE 13%
FPI/AIF 8%
